SEC Form 4 · accession 0001638599-17-000720
Fortress Biotech, Inc. · FBIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Malcolm Hoenlein
Director
Period of report
Mar 10, 2017
Accepted (ET)
Jul 21, 2017 · 4:11 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001429260
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.001 | holding | — | — | — | 55,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Deferred Restricted Stock UnitsF2,F1 | $0.00 | Mar 10, 2017 | A | 16,666 | A | — | — | Common Stock | 16,666 | 49,998 | D |
Explanation of responses
- F1The Reporting Person was granted restricted stock units ("RSUs") for service as a director in 2015, vesting one-third annually beginning on March 12, 2016. The Reporting Person deferred receipt of all the common stock upon the vesting of the RSUs under the Issuer's Deferred Compensation Plan for Directors (the "Plan"). Each deferred RSU that has vested will be settled in one share of the Issuer's common stock at the time and in the manner set forth in the Plan.
- F2Upon the vesting of RSUs, the Reporting Person deferred the receipt of 16,666 shares of common stock and received instead 16,666 shares of deferred RSUs. Page